All Posts By

Smartkarma Daily Briefs

Daily Brief Industrials: Adani Enterprises, Mirae Asset Tiger Top 10 ETF, Rainbow Robotics, Ihara Science, Natural Gas and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Adani Family Sells Stakes To GQG
  • Long Short Setup Candidate: Posco Holdings & Celltrion with TIGER Top 10 Rebalancing
  • KOSDAQ150 Index Rebalance Preview: Potential Adds Outperform Deletes by 50% in 4 Months, EXIT!
  • Ihara Science (5999 JP) – Not Over But Not a Great Look
  • US Large-Sized Farms Increase – Due to Input Cost Pressure // The Fall of The Petrodollar

Adani Family Sells Stakes To GQG

By Travis Lundy

  • Late Thursday night, the Adani Group announced that the family entities had sold Rs 154bn or US$1.8bn+ of stock in four listed entities to Australian-listed GQG Partners (GQG AU)
  • GQG is a US$90bn AUM asset manager specialising in emerging markets. They bought stakes of 2.55-4.10% in each of four entities. 
  • This “increases” float, but doesn’t. As of now, this will partially offset one MSCI downweight in May, and will likely cause three FIF uplifts.

Long Short Setup Candidate: Posco Holdings & Celltrion with TIGER Top 10 Rebalancing

By Sanghyun Park

  • Celltrion and Posco Holdings will switch places. Although there is still time until the screening period, the market capitalization gap between them has already widened significantly.
  • Posco Holdings will likely welcome a passive inflow of 0.44x ADTV, whereas Celltrion is expected to face outflows of around 0.69x ADTV.
  • Ecopro BM entered the Top 20 (preliminary screening table) with a YTD stock price increase of 130%, becoming the first KOSDAQ-listed company to do so.

KOSDAQ150 Index Rebalance Preview: Potential Adds Outperform Deletes by 50% in 4 Months, EXIT!

By Brian Freitas

  • Two thirds of the way through the review period for the June rebalance, we see 9 potential changes to the KOSDAQ 150 Index (KOSDQ150 INDEX)
  • One-Way turnover is estimated at 3.5%. Impact on the expected deletions is a lot higher than the impact on the expected inclusions and shorts are building up on the deletes.
  • Since the start of the review period, the potential inclusions have outperformed the potential deletions by nearly 50% and the KOSDAQ 150 Index (KOSDQ150 INDEX) by over 20%.

Ihara Science (5999 JP) – Not Over But Not a Great Look

By Travis Lundy

  • Today after the close, Ihara Science (5999 JP) reported on TDNet a forthcoming change in the Tender Offer Registration Statement by MBO bidder N.I.M.
  • N.I.M. and normally-known-as-deep-value-activist NAVF (a.k.a. Nippon Active Value Fund), Ihara Science’s #2 shareholder, signed a Tender Offer Agreement whereby NAVF agreed to tender. 
  • It got a little more complicated 90mins later, but this was an announcement which did not need to be made. It begs the question of why. And what next.

US Large-Sized Farms Increase – Due to Input Cost Pressure // The Fall of The Petrodollar

By The Commodity Report

  • US Large-Sized Farms Increase – Due to Input Cost Pressure According to the Farms and Land in Farms Report by the USDA, the largest farms in the US that had sales of $1 million or more, now operate almost 26% of the country’s farmland.
  • The farms in this sales class have increased in size, while farms in every other sales class have either remained the same size or decreased.
  • According to the Farms and Land in Farms Report by the USDA, the largest farms in the US that had sales of $1 million or more, now operate almost 26% of the country’s farmland.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Health Care: Global Health (Medanta), IDEXX Laboratories, Shenzhen Edge Medical, Oryzon Genomics and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Global Health (MEDANTA IN): Solid 3Q and 9M Results; Continued Expansion to Drive Growth
  • IDEXX Laboratories Inc.: Initiation of Coverage – Business Strategy & Other Drivers
  • Pre-IPO Shenzhen Edge Medical – The Surgical Robot Business in China Is Proving Harder than Expected
  • Oryzon Genomics – Catalysts on the horizon in FY23

Global Health (MEDANTA IN): Solid 3Q and 9M Results; Continued Expansion to Drive Growth

By Tina Banerjee

  • Global Health (Medanta) (MEDANTA IN) reported double-digit growth in revenue, EBITDA, and net profit during Q3 and 9MFY23, driven by increasing footfalls, rising ARPOB, and faster-than-expected ramp-up of new hospitals.
  • The company plans to add 1,000–1,500 beds in next 2–3 years, with ~70% of the planned bed addition being at existing hospitals, thereby entailing lower capex per bed.
  • Recently, Medanta has announced a new asset light partnership to launch a 300-bed hospital in Indore under operations and management arrangement. The hospital is expected to commence operation in FY27.  

IDEXX Laboratories Inc.: Initiation of Coverage – Business Strategy & Other Drivers

By Baptista Research

  • IDEXX had a strong finish to the year, reflected in the company’s all-around beat in the last quarter.
  • Its revenues increased organically, driven by organic gains in CAG Diagnostic and strong growth in its water and software businesses.
  • Organic revenue growth in the quarter was supported by solid organic growth across its major business segments and growth in diagnostic imaging and veterinary software revenues.

Pre-IPO Shenzhen Edge Medical – The Surgical Robot Business in China Is Proving Harder than Expected

By Xinyao (Criss) Wang

  • MP1000 has strong technical strength, setting it apart from Toumai. SP1000’s advantages are more obvious and the competitive landscape is also better than multi-port surgical robots, indicating corner overtaking opportunity.
  • With favorable policy support, Shenzhen Edge Medical (SEM HK) is embracing a golden opportunity. But the commercialization outlook of surgical robots in China is actually not optimistic.
  • As a later-comer in surgical robots industry, without the synergy from parent company, Edge’s future sales performance could be even weaker. So, its valuation should be lower than Medbot.

Oryzon Genomics – Catalysts on the horizon in FY23

By Edison Investment Research

FY23 is shaping up to be a busy clinical year for Oryzon with readouts and trial initiations expected across its lead assets. The next major clinical milestone for iadademstat in oncology is the initiation of the Phase Ib FRIDA study in second-line FLT3+ relapsed/refractory (r/r) acute myeloid leukaemia (AML) patients with the trial expected to start imminently. Oryzon’s lead central nervous system (CNS) clinical asset, vafidemstat, is being assessed for the treatment of borderline personality disorder (BPD) in the Phase IIb PORTICO study. Interim data readouts are expected from the trial in Q123, which we view as the next major upcoming catalyst for investor attention. Our valuation of Oryzon remains largely unchanged at €869.0m or €15.6 per share (previously €846.7m or €15.5/share).


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Consumer: Invocare Ltd, S.M.Entertainment Co, Luckin Coffee, Coupang, Melco Resorts & Entertainment, Diageo PLC and more

By | Consumer, Daily Briefs

In today’s briefing:

  • InvoCare (IVC AU): TPG Capital Makes a Move
  • Kakao Announces a Tender Offer of SM Entertainment at 150,000 Won Per Share
  • Kakao’s Tender Offer to SM Ent Shareholders: Key Details of Disclosure Filed This Morning
  • [Luckin Coffee Inc. (LKNCY US) Earnings Review]: A Few Bright Spots in a Transactional Quarter
  • Coupang: Revenue & Profits Let Coupang Down, Valuation Is Still at a Significant Premium to Peers
  • Melco Resorts – Earnings Flash – FY 2022 Results – Lucror Analytics
  • Diageo: A Rare Gift From Mr. Market

InvoCare (IVC AU): TPG Capital Makes a Move

By Arun George

  • AFR reports that TPG Capital, through UBS, is seeking to acquire 14.4m or 10.00% of Invocare Ltd (IVC AU)‘s outstanding shares at A$12.65, a 41.3% premium to the undisturbed price.
  • If the aftermarket raid is successful, TPG will follow the tried-and-test private equity playbook of securing a pre-bid stake before lobbing a non-binding offer at A$12.65 per share
  • TPG has timed its move to take advantage of the post-results price slump. While not a knockout offer, it is a starting point for the Board to secure better terms.

Kakao Announces a Tender Offer of SM Entertainment at 150,000 Won Per Share

By Douglas Kim

  • On 7 March, Kakao Corp (035720 KS) announced a tender offer of up to 35% of outstanding shares of SM Entertainment at 150,000 won per share.
  • We believe that this will be a successful tender offer and the share price of SM Entertainment is likely to surge to near 150,000 won per share. 
  • The minority shareholders of SM Entertainment are cheering on as its share price appreciation will be nearly 96% from end of 2022 to the tender offer price of 150,000 won. 

Kakao’s Tender Offer to SM Ent Shareholders: Key Details of Disclosure Filed This Morning

By Sanghyun Park

  • Kakao and Kakao Entertainment each plan to purchase 4.167 million shares at ₩150,000 per share, totaling 8.33 million. This is a 14.5% premium to the last close.
  • The tendering ending date is March 26th, Sunday, so the actual ending date is March 24th. Since Korea adopts the T+2 settlement system, stocks must be purchased by the 22nd.
  • The price of SM may decline towards below the tender price relatively quickly as a large number of retail investors will likely bet on the prolonged proxy battle.

[Luckin Coffee Inc. (LKNCY US) Earnings Review]: A Few Bright Spots in a Transactional Quarter

By Shawn Yang

  • Luckin Coffee reported its 4Q22 revenue, non-GAAP operating income, and non-GAAP net income (9.1%), (11.4%), (57.9%) lower than our estimate. 
  • The store temporary close due to Covid impact is the main reason for revenue miss, and the higher income tax payment is the reason for the miss on NI.  
  • We expect Luckin to catch up the store expansion schedule in 1Q23 at 730 new stores, and reach to 10,500 total stores by the end of 2023. 

Coupang: Revenue & Profits Let Coupang Down, Valuation Is Still at a Significant Premium to Peers

By Oshadhi Kumarasiri

  • South Korea’s largest e-commerce company, Coupang (CPNG US) sank around 20% leading up to 4Q22 earnings. It dropped another 9% soon after the earnings report to around $14.0 per ADS.
  • Meanwhile, the valuation remains expensive compared to regional peers as Coupang is trading at an 80% premium to the second most expensive e-commerce name in the region.
  • If the share price breaks the trend line here, we think shares could go on to fall below the last year’s bottom of $8.98 per ADS.

Melco Resorts – Earnings Flash – FY 2022 Results – Lucror Analytics

By Leonard Law, CFA

Melco Resorts’ (MLCO) FY 2022 results were better than peers’, supported by strong earnings growth at its overseas assets (in the Philippines and Cyprus) amid a weak showing in Macau. In addition, management reported rosy earnings guidance for YTD 2023 (in line with those reported by peers).

Going forward, we forecast that the company’s revenue will reach 70-80% of the FY 2019 level, supported by a recovery in industry GGR to 50-60% of the 2019 level, as well as contributions from Studio City Phase 2 and City of Dreams Mediterranean from H2/23. This should allow MLCO to generate positive FCF and deleverage in FY 2023.

We move our recommendation to “Buy” on the MPEL curve from “Hold”.


Diageo: A Rare Gift From Mr. Market

By Vladimir Dimitrov, CFA

  • Diageo’s share price has been underperforming for far too long due to outside factors that have little to do with the business itself.
  • The premium brand portfolio in combination with the well-executed acquisition strategy creates a unique opportunity.
  • The company is well-positioned to retain and even improve its industry-leading margins.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Private Markets: Mobvoi: Focused on AI Technologies for Advanced Voice Interaction and Hardware-Software Integration and more

By | Daily Briefs, Private Markets

In today’s briefing:

  • Mobvoi: Focused on AI Technologies for Advanced Voice Interaction and Hardware-Software Integration

Mobvoi: Focused on AI Technologies for Advanced Voice Interaction and Hardware-Software Integration

By Douglas Kim

  • Mobvoi uses AI technology to improve the next generation human-machine interaction. The company’s key partners include Google and Volkswagen.
  • Mobvoi provides full-stack AI solutions for various hardware-software integration, voice interaction technology and engineering capabilities. The key sectors served include IoT, finance, telecommunications, F&B, and auto. 
  • Since the founding of the company in 2012, the company has raised US$253 million in funding. Major investors in the company include Sequoia Capital, ZhenFund, SIG, and Google. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief ECM: SBI Sumishin Net Bank Pre-IPO – Revised Forecast and Valuations – RoA or RoE? and more

By | Daily Briefs, ECM

In today’s briefing:

  • SBI Sumishin Net Bank Pre-IPO – Revised Forecast and Valuations – RoA or RoE?
  • Dida Pre-IPO: Losing Its Dominance
  • Samsung FN REIT: The First Major REIT IPO for Samsung Group
  • Pre-IPO Shenzhen Edge Medical – The Surgical Robot Business in China Is Proving Harder than Expected

SBI Sumishin Net Bank Pre-IPO – Revised Forecast and Valuations – RoA or RoE?

By Sumeet Singh

  • SBI Sumishin Net Bank (7163 JP) (SSNB) is now looking to raise around US$380m in its second listing attempt.
  • SBI Sumishin Net Bank is a Japanese digital bank set up as a 50-50 joint venture between Sumitomo Mitsui Trust Bank, Japan’s largest trust bank, and SBI Group.
  • In this note, we talk about our updated earnigns forecast and thoughts on valuations

Dida Pre-IPO: Losing Its Dominance

By Shifara Samsudeen, ACMA, CGMA

  • Chinese carpooling platform Dida (DIDA HK) has refiled for an IPO on the HKEx for the second time (in 2020 and 2021) and could raise around US$200m through the IPO.
  • Dida’s last two attempts were not successful and some news media outlets reported that Dida has got assurance from regulators to go ahead with the IPO.
  • In this insight, we take a look at the new data points from the company’s latest IPO filings.

Samsung FN REIT: The First Major REIT IPO for Samsung Group

By Douglas Kim

  • Samsung FN REIT is getting ready to complete its IPO in April 2023, which will be the first Samsung Group related REIT that will become public. 
  • The core real estate properties of Samsung FN REIT will include the ‘Daechi Tower’ and ‘S1 Building’ which have excellent locations in Seoul. 
  • We expect a huge demand for this IPO of Samsung FN REIT and we have a Positive view of this IPO. 

Pre-IPO Shenzhen Edge Medical – The Surgical Robot Business in China Is Proving Harder than Expected

By Xinyao (Criss) Wang

  • MP1000 has strong technical strength, setting it apart from Toumai. SP1000’s advantages are more obvious and the competitive landscape is also better than multi-port surgical robots, indicating corner overtaking opportunity.
  • With favorable policy support, Shenzhen Edge Medical (SEM HK) is embracing a golden opportunity. But the commercialization outlook of surgical robots in China is actually not optimistic.
  • As a later-comer in surgical robots industry, without the synergy from parent company, Edge’s future sales performance could be even weaker. So, its valuation should be lower than Medbot.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Thematic (Sector/Industry): Good Morning Japan |SPX Holds On..barely; Powell Testimony in Focus; NUGGET: AI & Japan Big Pharma and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • Good Morning Japan |SPX Holds On..barely; Powell Testimony in Focus; NUGGET: AI & Japan Big Pharma
  • China Aerospace & Defense Industry: Ways to Play the Rise in Defense Spending
  • Aviation, Should One Buy the Profit Recovery?
  • Weekly Sustainable Investing Surveyor: Week Ended March 3, 2023

Good Morning Japan |SPX Holds On..barely; Powell Testimony in Focus; NUGGET: AI & Japan Big Pharma

By Mark Chadwick

  • OVERSEAS.  SPX Clings to Positive gains – barely; Powell Testimony in Focus;  Commodities Weak on dissappointing China growth target; GS upgrade Apple to BUY; Telsa cuts prices (again)
  • JAPAN. NKY Futs Flat vs Cash; USDJPY 136; Progress on Japan-S.Korea Relation normalization; Public increasingly supports nuclear restarts;  Toyota rolls out BEV in China; Win for Rakuten in “Open Ran”
  • NUGGET. AI Development platforms are being rolled around across Japan’s manufacturing sector to improvement R&D efficiency. This has the potential to drive significant value, especially in Japan Big Pharma

China Aerospace & Defense Industry: Ways to Play the Rise in Defense Spending

By Osbert Tang, CFA

  • China’s defense budget will reach Rmb1.55trn in 2023, a 7.2% YoY increase and up from 7.1% in 2022. This also equals to 1.22% of GDP, vs. 1.2% in 2022. 
  • AviChina Industry & Technology H (2357 HK) has the most direct exposure to China’s aerospace and defense developments given its holdings in A-share defense stocks.
  • Avic Shenyang Aircraft (600760 CH) will benefit from its unique position as the key manufacturer of aircraft, parts and components for China’s combat fighter fleet.

Aviation, Should One Buy the Profit Recovery?

By Nurture Capital Advisory

  • Indigo and Spice Jet have turned to profits in Q3FY23.
  • Indian Aviation sector is at infancy and the large market is consolidating. 
  • However, rising ATF costs may restrict profit recovery, thus while valuations are reasonable and there is a long runway, it’s not yet the time to go aboard.

Weekly Sustainable Investing Surveyor: Week Ended March 3, 2023

By Water Tower Research

  • WTR Sustainable Index: During the week ended March 3, 2023, the WTR Sustainable Index performed in line with the broader market, rising 2.0% W/W versus the S&P 500 Index (up 1.9%), the Russell 2000 Index (up 2.0%), and the Nasdaq Composite Index (up 2.6%).
  • Energy Technology (8.5% of the index) drove the index performance, rising 4.4%, while Advanced Transportation Solutions (69.6% of the index) was up 1.2% and Industrial Climate and Ag Technology was up 3.4%.
  • Valuation: Based on forward 12-month consensus estimates, the current P/E ratio of the WTR Sustainable index is 25.0x versus 18.3x for the S&P 500.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Technical Analysis: International Business Machines Corp (IBM US) – TSS < 10 - Target Tactical 6-7% Upswing and more

By | Daily Briefs, Technical Analysis

In today’s briefing:

  • International Business Machines Corp (IBM US) – TSS < 10 - Target Tactical 6-7% Upswing

International Business Machines Corp (IBM US) – TSS < 10 - Target Tactical 6-7% Upswing

By David Coloretti, CMT

  • IBM US peaked at 153.21 in December 2022 and has declined more than 15% in the subsequent 12 weeks.
  • Last week’s low of 127.71 was plagued by extreme ST momentum failure and this new 4 month low was quick to fail and reverse.
  • Our TSS methodology triggered a TSS < 10 at the low and justifies a further 6-7% upswing in the coming 1-2 weeks.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Credit: Melco Resorts – Earnings Flash – FY 2022 Results – Lucror Analytics and more

By | Credit, Daily Briefs

In today’s briefing:

  • Melco Resorts – Earnings Flash – FY 2022 Results – Lucror Analytics
  • Morning Views Asia: Country Garden Holdings Co, Lippo Malls Indonesia Retail Trust, NagaCorp Ltd

Melco Resorts – Earnings Flash – FY 2022 Results – Lucror Analytics

By Leonard Law, CFA

Melco Resorts’ (MLCO) FY 2022 results were better than peers’, supported by strong earnings growth at its overseas assets (in the Philippines and Cyprus) amid a weak showing in Macau. In addition, management reported rosy earnings guidance for YTD 2023 (in line with those reported by peers).

Going forward, we forecast that the company’s revenue will reach 70-80% of the FY 2019 level, supported by a recovery in industry GGR to 50-60% of the 2019 level, as well as contributions from Studio City Phase 2 and City of Dreams Mediterranean from H2/23. This should allow MLCO to generate positive FCF and deleverage in FY 2023.

We move our recommendation to “Buy” on the MPEL curve from “Hold”.


Morning Views Asia: Country Garden Holdings Co, Lippo Malls Indonesia Retail Trust, NagaCorp Ltd

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Crypto: Sporting Crypto – 6th March 2023: Is AR the New Meta? and more

By | Crypto, Daily Briefs

In today’s briefing:

  • Sporting Crypto – 6th March 2023: Is AR the New Meta?
  • The Future of Fiat On-Ramps

Sporting Crypto – 6th March 2023: Is AR the New Meta?

By Sporting Crypto

  • Through my work and writing, I’ve been thinking more and more about an area that I’m not an expert in: gaming.
  • And when we combine the word ‘Gaming’ with ‘Web3’ — there is a buzz and sense of excitement from most.
  • Specifically, it’s all the rage when people talk about NFTs and the future of gaming.

The Future of Fiat On-Ramps

By Kaiko

  • Silvergate is in deep trouble. On March 1, the “crypto bank” revealed in a regulatory filing that it could soon be “less than well capitalized.”
  • The news prompted Coinbase, Paxos, Galaxy Digital and a host of other large crypto enterprises to drop Silvergate as a banking partner. Why does this matter? 
  • The “fiat problem” has long plagued crypto markets: to buy bitcoin, you at some point need to interact with the traditional banking system.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Equity Bottom-Up: China Internet Weekly (6Mar2023): JD and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • China Internet Weekly (6Mar2023): JD, Kuaishou, Baidu, Weibo, Vipshop
  • Taiwan Tech Weekly: HP Says No Major PC Recovery in 2023E; Signs of Display ICs Early Turn-Around?
  • [Bilibili Inc. (BILI US) Target Price Change]: Minor Protection Would Be a Pending Issue
  • [Luckin Coffee Inc. (LKNCY US) Earnings Review]: A Few Bright Spots in a Transactional Quarter
  • Coupang: Revenue & Profits Let Coupang Down, Valuation Is Still at a Significant Premium to Peers
  • Global Health (MEDANTA IN): Solid 3Q and 9M Results; Continued Expansion to Drive Growth
  • IDEXX Laboratories Inc.: Initiation of Coverage – Business Strategy & Other Drivers
  • Valero Energy: Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (02/23)
  • Diageo: A Rare Gift From Mr. Market
  • Enterprise Product Partners: Major Drivers

China Internet Weekly (6Mar2023): JD, Kuaishou, Baidu, Weibo, Vipshop

By Ming Lu

  • Two JD.com departments began to try fresh food front-line warehouse again.
  • Radio and Television Administration plans to clean the content in short video.
  • Herman Yu, Baidu’s chief strategy officer and formerly CFO, just resigned.

Taiwan Tech Weekly: HP Says No Major PC Recovery in 2023E; Signs of Display ICs Early Turn-Around?

By Vincent Fernando, CFA

  • Hon Hai reports YoY increase in January + February sales, maintains outlook.
  • Hewlett Packard results: CEO says does not expect significant PC recovery in FY2023E. Fitipower results show display ICs potentially bottoming earlier than most segments.
  • Memory Monitor: Two latest signals indicate lower margins and extended high inventories; biased Long Micron vs. Short Nanya Tech.

[Bilibili Inc. (BILI US) Target Price Change]: Minor Protection Would Be a Pending Issue

By Shawn Yang

  • BILI’s 4Q22 top line was basically in line, while non-GAAP net loss beat cons. by 8.28%. We largely dial down 2023 revenue forecast. 
  • Moreover, we also suggest that recent meeting by the National Radio and Television Administration (NRTA) to curb short video addiction for minor protection would heavily impact BILI.
  • Maintain SELL and cut TP to US$ 15.4, which implies 1.85X PS in 2023.

[Luckin Coffee Inc. (LKNCY US) Earnings Review]: A Few Bright Spots in a Transactional Quarter

By Shawn Yang

  • Luckin Coffee reported its 4Q22 revenue, non-GAAP operating income, and non-GAAP net income (9.1%), (11.4%), (57.9%) lower than our estimate. 
  • The store temporary close due to Covid impact is the main reason for revenue miss, and the higher income tax payment is the reason for the miss on NI.  
  • We expect Luckin to catch up the store expansion schedule in 1Q23 at 730 new stores, and reach to 10,500 total stores by the end of 2023. 

Coupang: Revenue & Profits Let Coupang Down, Valuation Is Still at a Significant Premium to Peers

By Oshadhi Kumarasiri

  • South Korea’s largest e-commerce company, Coupang (CPNG US) sank around 20% leading up to 4Q22 earnings. It dropped another 9% soon after the earnings report to around $14.0 per ADS.
  • Meanwhile, the valuation remains expensive compared to regional peers as Coupang is trading at an 80% premium to the second most expensive e-commerce name in the region.
  • If the share price breaks the trend line here, we think shares could go on to fall below the last year’s bottom of $8.98 per ADS.

Global Health (MEDANTA IN): Solid 3Q and 9M Results; Continued Expansion to Drive Growth

By Tina Banerjee

  • Global Health (Medanta) (MEDANTA IN) reported double-digit growth in revenue, EBITDA, and net profit during Q3 and 9MFY23, driven by increasing footfalls, rising ARPOB, and faster-than-expected ramp-up of new hospitals.
  • The company plans to add 1,000–1,500 beds in next 2–3 years, with ~70% of the planned bed addition being at existing hospitals, thereby entailing lower capex per bed.
  • Recently, Medanta has announced a new asset light partnership to launch a 300-bed hospital in Indore under operations and management arrangement. The hospital is expected to commence operation in FY27.  

IDEXX Laboratories Inc.: Initiation of Coverage – Business Strategy & Other Drivers

By Baptista Research

  • IDEXX had a strong finish to the year, reflected in the company’s all-around beat in the last quarter.
  • Its revenues increased organically, driven by organic gains in CAG Diagnostic and strong growth in its water and software businesses.
  • Organic revenue growth in the quarter was supported by solid organic growth across its major business segments and growth in diagnostic imaging and veterinary software revenues.

Valero Energy: Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (02/23)

By Baptista Research

  • Valero had a solid year-end, with refineries running at 97% of their capacity in a positive refining margin situation.
  • Besides, significantly discounted sour crude oils and fuel oils helped its refinery.
  • High natural gas costs in Europe also encouraged refiners to process sweet crude oils rather than sour crude oils, placing additional pressure on sour crude oils.

Diageo: A Rare Gift From Mr. Market

By Vladimir Dimitrov, CFA

  • Diageo’s share price has been underperforming for far too long due to outside factors that have little to do with the business itself.
  • The premium brand portfolio in combination with the well-executed acquisition strategy creates a unique opportunity.
  • The company is well-positioned to retain and even improve its industry-leading margins.

Enterprise Product Partners: Major Drivers

By Baptista Research

  • Enterprise Product Partners delivered a mixed set of results in the quarter.
  • Enterprise moved a record 11.2 million barrels of oil equivalent per day which helped it deliver an all-around beat.
  • They believe that a wide gas-to-crude differential could result in a considerable cost advantage for American petrochemicals globally.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars